Clinical Trial Update: A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism [Phase 2]

View source ↗

Summary

A multicenter, open-label extension study of cinacalcet (AMG 073) assesses long-term safety and efficacy in individuals with primary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• cinacalcet (cinacalcet hydrochloride)

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Primary | Phase 2 | Status: COMPLETED